Rigel Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Rigel Pharmaceuticals

05/08/2025 22:02

Rigel Pharmaceuticals Inc RIGL.OQ reported quarterly adjusted earnings of $3.28​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -6 cents.  The mean expectation of five analysts for the quarter was for earnings of $2.58 per share. Wall Street expected results to range from $2.44  to $2.78 per share.

Revenue rose 176% to $101.69 million from a year ago; analysts expected $88.95 million.

Rigel Pharmaceuticals Inc's reported EPS for the quarter was $3.28​.

The company reported quarterly net income of $59.61 million.

Rigel Pharmaceuticals Inc shares had risen by 21.0% this quarter and gained 34.8% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 152.1% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Rigel Pharmaceuticals Inc is $23.50, about 3.5% above its last closing price of $22.67

This summary was machine generated from LSEG data August 5 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
2.58
3.28
Beat
Mar. 31 2025
0.09
0.63
Beat
Dec. 31 2024
0.47
0.80
Beat
Sep. 30 2024
0.06
0.70
Beat